SLXN · Silexion Therapeutics Corp Ordinary Shares
View on chartInsiders & Stakes
| Levin Ilan Director | ▲ Buy | Grant | 456,970 Shares held | 9/15/2025 | View profile |
| Noy Shlomo Director | ▲ Buy | Grant | 25,399 Shares held | 2/20/2026 | View profile |
| Lushi Avner Director | ▲ Buy | Grant | 25,399 Shares held | 2/20/2026 | View profile |
| Hadar Ilan Chairman and CEO | ▲ Buy | Grant | 16,547 Shares held | 6/4/2026 | View profile |
| Horenshtein Hadar Mirit CFO and Secretary | ▲ Buy | Grant | 12,515 Shares held | 6/4/2026 | View profile |
| Alon Ruth Director | ▲ Buy | Grant | 10,228 Shares held | 2/20/2026 | View profile |
| Abramov Dror Yosef Director | ▲ Buy | Grant | 10,180 Shares held | 2/20/2026 | View profile |
| Shirvan Mitchell CSO and CDO | ▲ Buy | Grant | 8,789 Shares held | 6/4/2026 | View profile |
| Peled Amnon Director | ▲ Buy | Grant | 8,237 Shares held | 2/20/2026 | View profile |
Transaction History
| Shirvan Mitchell | ▲ Buy | Grant | 6,000 | $0 | 6/4/2026 |
| Horenshtein Hadar Mirit | ▲ Buy | Grant | 7,500 | $0 | 6/4/2026 |
| Hadar Ilan | ▲ Buy | Grant | 10,000 | $0 | 6/4/2026 |
| Shirvan Mitchell | ▼ Sell | Open Market | 22,818 | $31K | 3/26/2026 |
| Hadar Ilan | ▲ Buy | Grant | 64,350 | $0 | 2/20/2026 |
| Lushi Avner | ▲ Buy | Grant | 9,091 | $0 | 2/20/2026 |
| Peled Amnon | ▲ Buy | Grant | 7,576 | $0 | 2/20/2026 |
| Abramov Dror Yosef | ▲ Buy | Grant | 9,091 | $0 | 2/20/2026 |
| Noy Shlomo | ▲ Buy | Grant | 9,091 | $0 | 2/20/2026 |
| Alon Ruth | ▲ Buy | Grant | 9,091 | $0 | 2/20/2026 |
| Shirvan Mitchell | ▲ Buy | Grant | 49,726 | $0 | 2/20/2026 |
| Horenshtein Hadar Mirit | ▲ Buy | Grant | 49,726 | $0 | 2/20/2026 |
| Levin Ilan | ▲ Buy | Grant | 450,000 | $1.8M | 9/15/2025 |
| Levin Ilan | ▼ Sell | Other | 5,550 | $0 | 8/7/2025 |
| Abramov Dror Yosef | ▲ Buy | Grant | 794 | $0 | 2/9/2025 |
| Alon Ruth | ▲ Buy | Grant | 794 | $0 | 2/9/2025 |
| Noy Shlomo | ▲ Buy | Grant | 1,587 | $0 | 2/9/2025 |
| Lushi Avner | ▲ Buy | Grant | 1,587 | $0 | 2/9/2025 |
| Peled Amnon | ▲ Buy | Grant | 661 | $0 | 2/9/2025 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Silexion Reports First Patient Dosed in Phase 2/3 SIL204 Trial
Silexion Therapeutics announced that the first patient has been successfully dosed in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer. The milestone indicates progress toward evaluating the drug’s safety and efficacy in a larger patient group. The announcement may influence investor interest as the company moves closer to potential regulatory submissions. The trial’s results will be key to assessing SIL204’s future development path.
Silexion Reports First Patient Dosed in Phase 2/3 SIL204 Trial. Silexion Therapeutics announced that the first patient has been successfully dosed in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer. The milestone indicates progress toward evaluating the drug’s safety and efficacy in a larger patient group. The announcement may influence investor interest as the company moves closer to potential regulatory submissions. The trial’s results will be key to assessing SIL204’s future development path.